Vinod Pullarkat is a Hematology physician affiliated with City Of Hope National Medical Center. OpenAlex indexes 556 publications with 15,539 citations (h-index 54); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 Duarte Rd
Duarte, CA 910103012
Telephone
626-256-4673Provider last certified this registry record 29 Oct 2020.
Clinical trials
- 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
Sponsor: City of Hope Medical Center
- 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Sponsor: City of Hope Medical Center
- Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
Sponsor: City of Hope Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
37 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year202519 payments$42,178openpaymentsdata.cms.gov ↗
- Novartis Pharmaceuticals CorporationProgram year202535 payments$35,987openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202511 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
53.2%Factor Xa inhibitor22.1%Eliquis71%Xarelto29%Part D<11 patientsVitamin K antagonist16%Warfarin Sodium100%Part D≥23 patients+ 2 more classes in this area
Cancer & immunology
28.2%Kinase inhibitor24.4%Jakafi83%Iclusig17%Part D<11 patientsBCL-2 Inhibitor3.8%Venclexta100%Part D<11 patientsAnti-infectives
9.7%Short-acting sulfonamides6.1%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsHepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor3.6%Entecavir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long‐term follow‐up of <scp>VIALE‐A</scp>: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia
American Journal of Hematology
2024 - Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria
New England Journal of Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Yuman Fong, MD
City Of Hope National Medical Center
Ravi Salgia, MD, PhD
City Of Hope National Medical Center
Stephen Gruber, MD
City Of Hope National Medical Center
Tanya Siddiqi, MD
City Of Hope National Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”